| Kitsize | 12x8 |
| Method | ELISA |
| Incubationtime | 1x18h,2x30min. |
| Standardrange | 0-500IU/ml;cut-off30IU/ml |
| Specimen/Volumes | 75µlserum |
| Substrate/isotope | TMB450nm |
| RegulatoryStatus: | Forresearchuseonly |
TheGAD65-AbELISAisasolidphaseenzymeimmunoassayemployingrecombinanthumanglutamatedecarboxylase65kDaisoform(GAD65)forthequantitativeandqualitativedetectionofantibodiesagainsthumanGAD65inhumanserum.Theassayisatoolinthediagnosisoftype1diabetesmellitus.
Beforeclinicalonset,type1diabetesisoftencharacterizedbycirculatingautoantibodiesagainstavarietyofpancreaticisletcellantigens,includingglutamicaciddecarboxylase(mainlytheGAD65kDaisoform),tyrosinephosphatase(IA2)andinsulin.TheseautoantibodiesareimportantpreclinicalMarkers,whichmayalreadybepresentforyearsbeforetheactualdiagnosisofdiabetesandothermetabolicassaysstillgivenormalvalues.
Forthispurpose,IBLInternationaloffersappropriateELISAs,whichreliablyandefficientlydetecttheautoantibodies.
AdvantagesofGAD65-AbundIA2-AbELISAs:
- Samplevolume:>75µLSerum
- Commonreagents(samplebuffer,washbuffer,substrateandstopsolution)
- CalibrationagainsttheWHOreferencereagent:NIBSCcode97/550
- Standardrange:0-500IU/mLorcut-off30IU/mL
- Choiceofqualitativeorquantitativeresultinterpretation
- Simplifiedautomation
| GAD65-AbELISA | IA2-AbELISA | |
| Catalog-Nr. | RE70371 | RE70381 |
| Sensitivity | 92% | 70% |
| Specifity | 98% | 99% |
| Incubationconditions | 1x18,3x30min | 1x18,3x30min |
